As Director of sales in EMEA at Thermo Fisher, I lead the EMEA Senior Account Manager (SAM) team. • Responsible for the overall strategy and management of the EMEA SAM team• Setting sales targets and action plans. I lead the team and support them to make connections and build long-lasting relationships with new and key clients across Europe. We support our clients in all the aspects of their clinical supply. Our goal is to enable our customers to provide the treatments to the patients on time wherever they are in the world. I work with each team member and coach them to reach their best potentials. That include ensuring skills development and career progression.

• Identify and progress new opportunities within specific accounts• Actively work with operational teams to protect existing business and discuss future opportunities• Continually monitor and review personal performance against plan• Own and manage the quoting process ensuring the most effective solution for your client• Manage client expectations by involving other Fisher Clinical Services personnel, such as Client Services, Operations, Subject Matter Experts (SMEs) and Executive Leadership Team (ELT) Members, in order to build a horizontally integrated relationship.

Sharp Clinical Services is one of the world’s leading providers of clinical supply chain solutions for pharmaceutical and biotechnology companies.My role was to build a robust business pipeline by spotting project opportunities from direct interactions with pharma, biotech companies and CROs.I’m in charge of FR, Benelux and the Nordic region with key responsabilities in: • Delivering the territory sales target• Owning and driving the entire business development cycle• Traveling frequently to be face-to-face with influencers and decision makers

Hybrigenics is a complete solution provider of cutting-edge technologies dedicated to the study of protein interactions and target id. duties and accomplishments:• Managing an important pipeline• Account management of 2 key accounts in Belgium and Germany • Manage 2 distributors in Asia (Japan and China) and in negotiation with others• Commercial prospection and onsite meeting with customers to negotiate and close deals• Drive compliance of MSA and SOW• Manage P&L for assigned accounts in collaboration with the Project Manager• Participating in international scientific conferences (22 in total) in Europe (FR, GR and UK) and Asia (Japan, Korea, Singapore)• Developed Market studies and Business plans to increase GCC market (KSA, Qatar, Bahrein, Kuwait, UAE)

The LFB group is a biopharmaceutical company specialising in medicinal products derived from living organism.Market study / SFEForecastingCompetitive, Strategic and scientific analysis

HALTYS is a consulting company specialized in strategy, marketing and business development for medical devices and biopharma sector.Commercial prospecting, targeting new customers, partners and opportunities research and evaluationMarket studies/ SFE, Forecasting, Business intelligence, scientific and competitive analysis, positioning and new product developmentMarket access: Helping international drugs and medical device companies to enter the French market

Onxeo designs and develops innovative drugs with unique mechanisms of action in rare and orphan cancers.My role was for in & out-licensing:• Strategic and competitive analysis and Databases screening • Market study: positioning and price evaluation of the studied products• Participation in the promotion of a product in France• Reporting and slideshows preparation to the Executive Strategic Marketing and Business Development team• Meeting scientists and discussion with KOL to know their evaluation on the interested products• Writing and analyzing scientific reports (preclinical and clinical)

Title: Implication of "Polycomb group Proteins" in cancer and cell cycle during development.Polycomb group Proteins (PcG) are evolutionary conserved proteins very important in many aspects of the development. By studying these proteins during development we discovered that alteration of their normal expression will induce a dysfunction in the natural cell division and in some cases leading to tumors formation and metastases.

Alternative splicing and the function of SR proteins in the protein diversity required for the development.